- Email: [email protected]
For better communications: Conference of pharmacy journal editors
I
for better conference of communications pharmacy journal editors
T
o find out what pharmacists and advertisers expect of pharmacy journals and to discover how pharmacy journals can meet the profession's needs, APHA is sponsoring a day-long conference of pharmacy journal editors on November 20 at the New York Hilton in New York City . This is the first such conference for pharmacy journals although medical and dental journals have had many successful conferences of this kind. Two panel discussions and four talks will highlight the two sessions and at the luncheon meeting Austin Smith, MD, president of the Pharmaceutical Manufacturers Association, will be headline speaker. His to pic- The Physician-Pharmacist-Patient Relationship. Giving editors an opportunity to find out what their readers want in a journal will be three panelists-Rosario J. Mannino, New Jersey community pharmacist; Louis P. Jeffrey, New York hospital pharmacist, and Linwood F .
Tice, pharmaceutical educator. Their discussion of what pharmacists look for in pharmacy journals will open the morning session. Presiding during this portion of the conference will be Robert E . Abrams, ACA executive secretary . Maxwell James, manager, trade relations, Lederle Laboratories, will present ano ther side of the picture in his talk on what the advertiser looks for in pharmacy journals. Climaxing the morning session, William S. Apple, APHA executive director, will take an overall look at pharmacy publications in his address on professional journals or trade publications. Following the luncheon at which APHA treasurer, Hugo H. Schaefer, will preside, Winton B. Rankin, assistant FDA commissioner, will provide his audience with an insight ;)n how FDA laws affect pharmacy journal ads. His talk will introduce the afternoon session gaveled by George B. Griffenhagen, director, APHA division of communications.
The session will continue with a discussion of the role the advertising agency has in pharmacy pUblications. Outlining this role will by Henry Halpern, vice president, media and marketing, Sudler and Hennessey. Concluding the day-long conference, three panelists will describe how a publication should be evaluated. Scheduled panelists include Theodore Caplow, professo r of the department of sociology, Columbia University, and Madeline Oxford Holland, pharmaceutical journalist. Attending the meeting by invitation only will be publishers, editors, media buyers, advertising managers, marketing managers and trade relations managers of the prescription drug industry. The conference was organized at the request of several state association secretaries after APHA Executive Director Apple emphasized the importance of improving the standards of pharmacy journal editorial content and advertising . •
....... .. ... . ... .. .. ................ .. ... . .. . . . . ...... . FDA New Drug Applications --Notice of Approvals As provided in § 130.33 of the FDA regulations (21 CFR 130.33; 28 FR 6377), notice has been given of the following new drugs for which applications have been approved. This list is published for the information of pharmacists but is not intended t o advise on the use of the products. Drugs listed may include some now approved for distribution by the applicants but previously marketed by other firms. This list covers new drug applications approved during July 1963. Established name (if any) or active ingredients
Trade name
Class of compound
Applicant
Isoproterenol sulfate
sympathomimetic
Meprobamate Meprobamate Meprobamate Meprobamate Vincristine sulfate Meprobamate Meprobamate Meprobamate Metronidazole
tranquili zer tranquilizer tranquilizer tranquili zer antileukem ia agent tranquilizer tranquilizer tranquilizer trichomona cidal agent
Merc k, Sharp, and Dohme Research La boratories Halsey Drug Co. , Inc _ Towne, Paulsen and Co., Inc. Stanley Drug Products, In c. Davis-Edwards Pharmacal Corp . Eli Lilly and Co . Richlyn Laboratories , Inc. Bates Laboratories, In c. Philadelphia Laboratories, In c . G. D. Searle and Co.
tranquilizer tranquilizer tranquilizer tranquilizer tranquilizer tranquilizer
Vita mix Pharmaceuticals, In c . Chase Chemical Co . Rabin-Winters Corp . Leo Linden Laboratories , Inc. Nysco Laboratories, Inc . Premo Pharmaceutica l Laboratories . Inc .
Meprobamate Meprobamate Meprobamate Meprobamate Meprobamate Meprobamate
554
Oncovin Ampoules
Flagyl oral tablets, Fla gyl vaginal tablets
Journal of the AMERICAN PHARMACEUTICAL ASSOCIATION
Date approved
How dispen sed
July 1
~
July 3 July July July July July July July
8 10 10 15 17 17 18
~ ~ ~ ~ ~ ~ ~ ~ ~
July July July July July July
18 19 19 22 23 26
~
n n n R R
for better conference of communications pharmacy journal editors
T
o find out what pharmacists and advertisers expect of pharmacy journals and to discover how pharmacy journals can meet the profession's needs, APHA is sponsoring a day-long conference of pharmacy journal editors on November 20 at the New York Hilton in New York City . This is the first such conference for pharmacy journals although medical and dental journals have had many successful conferences of this kind. Two panel discussions and four talks will highlight the two sessions and at the luncheon meeting Austin Smith, MD, president of the Pharmaceutical Manufacturers Association, will be headline speaker. His to pic- The Physician-Pharmacist-Patient Relationship. Giving editors an opportunity to find out what their readers want in a journal will be three panelists-Rosario J. Mannino, New Jersey community pharmacist; Louis P. Jeffrey, New York hospital pharmacist, and Linwood F .
Tice, pharmaceutical educator. Their discussion of what pharmacists look for in pharmacy journals will open the morning session. Presiding during this portion of the conference will be Robert E . Abrams, ACA executive secretary . Maxwell James, manager, trade relations, Lederle Laboratories, will present ano ther side of the picture in his talk on what the advertiser looks for in pharmacy journals. Climaxing the morning session, William S. Apple, APHA executive director, will take an overall look at pharmacy publications in his address on professional journals or trade publications. Following the luncheon at which APHA treasurer, Hugo H. Schaefer, will preside, Winton B. Rankin, assistant FDA commissioner, will provide his audience with an insight ;)n how FDA laws affect pharmacy journal ads. His talk will introduce the afternoon session gaveled by George B. Griffenhagen, director, APHA division of communications.
The session will continue with a discussion of the role the advertising agency has in pharmacy pUblications. Outlining this role will by Henry Halpern, vice president, media and marketing, Sudler and Hennessey. Concluding the day-long conference, three panelists will describe how a publication should be evaluated. Scheduled panelists include Theodore Caplow, professo r of the department of sociology, Columbia University, and Madeline Oxford Holland, pharmaceutical journalist. Attending the meeting by invitation only will be publishers, editors, media buyers, advertising managers, marketing managers and trade relations managers of the prescription drug industry. The conference was organized at the request of several state association secretaries after APHA Executive Director Apple emphasized the importance of improving the standards of pharmacy journal editorial content and advertising . •
....... .. ... . ... .. .. ................ .. ... . .. . . . . ...... . FDA New Drug Applications --Notice of Approvals As provided in § 130.33 of the FDA regulations (21 CFR 130.33; 28 FR 6377), notice has been given of the following new drugs for which applications have been approved. This list is published for the information of pharmacists but is not intended t o advise on the use of the products. Drugs listed may include some now approved for distribution by the applicants but previously marketed by other firms. This list covers new drug applications approved during July 1963. Established name (if any) or active ingredients
Trade name
Class of compound
Applicant
Isoproterenol sulfate
sympathomimetic
Meprobamate Meprobamate Meprobamate Meprobamate Vincristine sulfate Meprobamate Meprobamate Meprobamate Metronidazole
tranquili zer tranquilizer tranquilizer tranquili zer antileukem ia agent tranquilizer tranquilizer tranquilizer trichomona cidal agent
Merc k, Sharp, and Dohme Research La boratories Halsey Drug Co. , Inc _ Towne, Paulsen and Co., Inc. Stanley Drug Products, In c. Davis-Edwards Pharmacal Corp . Eli Lilly and Co . Richlyn Laboratories , Inc. Bates Laboratories, In c. Philadelphia Laboratories, In c . G. D. Searle and Co.
tranquilizer tranquilizer tranquilizer tranquilizer tranquilizer tranquilizer
Vita mix Pharmaceuticals, In c . Chase Chemical Co . Rabin-Winters Corp . Leo Linden Laboratories , Inc. Nysco Laboratories, Inc . Premo Pharmaceutica l Laboratories . Inc .
Meprobamate Meprobamate Meprobamate Meprobamate Meprobamate Meprobamate
554
Oncovin Ampoules
Flagyl oral tablets, Fla gyl vaginal tablets
Journal of the AMERICAN PHARMACEUTICAL ASSOCIATION
Date approved
How dispen sed
July 1
~
July 3 July July July July July July July
8 10 10 15 17 17 18
~ ~ ~ ~ ~ ~ ~ ~ ~
July July July July July July
18 19 19 22 23 26
~
n n n R R